Control of established melanoma by cd27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8+ T cells

Journal of Immunotherapy

Volumn 33, Issue 8, 2010, Pages 769-779

  Roberts, Drew J ^a   Franklin, Nathan A ^a   Kingeter, Lara M ^a   Yagita, Hideo ^b   Tutt, Alison L ^c   Glennie, Martin J ^c   Bullock, Timothy N J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

immunotherapy, CD8+ T cells, CD27, FoxP3, PD 1

Indexed keywords

AT 124 1; CANCER VACCINE; CD27 ANTIGEN; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; RM 27 3E5; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG EFFICACY; LUNG METASTASIS; MELANOMA; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL GROWTH PROCESSES; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 77958059390     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ee238f     Document Type: Article

References (46)

1. Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
2. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004; 4:941-952.
3. Cote AL, Usherwood EJ, Turk MJ. Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res. 2008;68:1614-1617.
4. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562-567.
5. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
6. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T-cell accumulation and effector function in murine self-and tumor-tolerance systems. J Clin Invest. 2007;117: 3383-3392.
7. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
8. Den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells In vivo. J Exp Med. 2000;192:1685-1696.
9. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965. (Pubitemid 24196166)
10. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling [see comments]. Nature. 1998;393:478-480.
11. + T-helper and a T-killer cell [see comments]. Nature. 1998;393:474-478.
12. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
13. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
14. Ahonen CL, Wasiuk A, Fuse S, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008;111: 3116-3125.
15. Assudani D, Cho HI, DeVito N, et al. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res. 2008; 68:9892-9899.
16. Wells JW, Cowled CJ, Farzaneh F, et al. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol. 2008;181:3422-3431.
17. + T cells. J Immunol. 2005;174:710-717.
18. French RR, Taraban VY, Crowther GR, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimula-tion. Blood. 2007;109:4810-4815.
19. Sanchez PJ, McWilliams JA, Haluszczak C, et al. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol. 2007;178:1564-1572.
20. Taraban VY, Rowley TF, Al Shamkhani A. Cutting edge: a critical role for CD70 in CD8 T-cell priming by CD40-licensed APCs. J Immunol. 2004;173:6542-6546.
21. Hendriks J, Gravestein LA, Tesselaar K, et al. CD27 is required for generation and long-term maintenance of T-cell immunity. Nat Immunol. 2000;1:433-440.
22. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T-cell pool. J Exp Med. 2003;198: 1369-1380.
23. + T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med. 2007;204:1095-1106.
24. + T cells for IL-12-induced Th1 cell development. Int Immunol. 2007;19:713-718.
25. + T-cell response after protein immunization. J Immunol. 2008;181:1071-1082.
26. Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T-cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002;3:83-90.
27. Takeda K, Oshima H, Hayakawa Y, et al. CD27-mediated activation of murine NK cells. J Immunol. 2000;164:1741-1745.
28. + T-cell tolerance and permits effective immunity. Immunity. 2008;29:934-946.
29. + T-cell formation. J Exp Med. 2004;199:1595-1605.
30. + T-cell immunity by immature dendritic cells in a vaccination setting. Blood. 2009;113:5167-5175.
31. Sumi T, Ishida W, Ojima A, et al. CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in mice. Immunol Lett. 2008;119:91-96.
32. + T cells and enhance tumor control. J Immunol. 2007;179: 5829-5838.
33. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic t lymphocyte-associated antigen 4 blockade and depletion of cd25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic t lymphocyte responses. J Exp Med. 2001;194:823-832.
34. + T cells. Cancer Res. 2004;64:1140-1145.
35. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114: 1537-1544.
36. + T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29-37.
37. Blattman JN, Grayson JM, Wherry EJ, et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003;9:540-547.
38. + T-cell anergy in vivo. J Immunol. 2009;182:6682-6689.
39. + T cells are restricted by the up-regulation of PD-1. J Immunol. 2009;182:4244-4254.
40. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176:1517-1524.
41. Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006;66: 4904-4912.
42. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T-cell apoptosis. J Exp Med. 2009;206:1103-1116.
43. Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol. 2002;169:1792-1800.
44. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3:609-620.
45. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002; 109:651-659.
46. Gray JC, French RR, James S, et al. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodula-tory antibodies. Eur J Immunol. 2008;38:2499-2511.